Burning Rock Declares Its Founder’s Acquisition of Its ADSs

(SeaPRwire) –   GUANGZHOU, China, April 02, 2026 — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a leader in applying next generation sequencing (NGS) technology to precision oncology, today announced that its founder, chairman, and CEO, Mr. Yusheng Han, has acquired 31,487 of the Company’s American Depositary Shares (ADSs) from the open market for US$546,603.90. This transaction was executed in full compliance with all relevant rules, regulations, and the Company’s insider trading policy. Following a prior purchase of 41,246 ADSs in the last post-earnings window, Mr. Han has now bought a total of 72,733 ADSs for US$1,358,325.18 across two successive post-earnings periods, demonstrating his strong belief in the Company’s business and future outlook.

Depending on market conditions and in accordance with applicable regulations, Mr. Han may make further purchases of the Company’s ADSs. Such acquisitions could occur through open-market dealings, privately negotiated or block trades, or other lawful methods. Any future buying activity will be influenced by several factors, including the stipulations of Rules 10b-18 and 10b5-1 under the Securities Exchange Act of 1934, alongside the Company’s insider trading policy.

About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR) is dedicated to guarding life through science, specializing in the use of next generation sequencing (NGS) technology in precision oncology. The Company’s operations encompass i) NGS-based testing to guide treatment selection for advanced cancer patients, and ii) cancer early detection, which has progressed from proof-of-concept research into the stage of clinical validation.

For more information about Burning Rock, please visit: ir.brbiotech.com.

Contact: IR@brbiotech.com